Clinical Trials Directory

Trials / Completed

CompletedNCT05630326

Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

Clinical, Laboratory, and Radiological Characteristics of Urinary Tract Infections in Infants With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
5,600 (actual)
Sponsor
Hamad Medical Corporation · Industry
Sex
All
Age
1 Year
Healthy volunteers
Not accepted

Summary

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli. Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Detailed description

In this retrospective, case-control study investigators will include all infants (0-1 year) with UTIs who were treated at Hamad General Hospital, pediatric division- PEC Doha, Qatar, using the electronic medical records from 1st January 2015 till January 1st, 2022, diagnosed by a positive urine culture. Investigators will look for the clinical manifestations, radiological and laboratory findings, renal scarring, ESBL-organisms, prevalence, median age, gender, and ethnic background. Participants are divided into two groups: early infancy and late infancy, ESBL UTIs and non-ESBL UTIs, and upper UTIs and lower UTIs. Finally, UTIs ESBL with COVID-19 and without COVID\_19.

Conditions

Interventions

TypeNameDescription
OTHERcomparing, prevalenceComparing infants with UTIs caused by ESBL organism, or non ESBL organism.
OTHERassessmentcomparing infants with UTIs caused by ESBL organism, or non ESBL organism.
OTHERassociationcomparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
OTHERevaluationcomparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Timeline

Start date
2023-03-01
Primary completion
2023-07-01
Completion
2023-07-20
First posted
2022-11-29
Last updated
2023-07-27

Locations

1 site across 1 country: Qatar

Source: ClinicalTrials.gov record NCT05630326. Inclusion in this directory is not an endorsement.